Scarica l'app Stockscreener
1.01
0.98%
-0.01
Pre-mercato:
1.00
-0.01
-0.99%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
Director Patricia Bradford Buys 6,500 Shares of Phio Pharmaceuti - GuruFocus
At $1.0127 a share, a Phio Pharmaceuticals (PHIO) director bought 6,500 shares. - Stock Titan
Phio Pharmaceuticals to Present Clinical Development Update - openPR.com
Phio Pharmaceuticals to Present Clinical Development Update & Upc - natlawreview.com
A CEO buys Phio Pharmaceuticals (PHIO) shares at $1.0289 each; reported direct holdings total 364,871 shares. - Stock Titan
Phio Pharmaceuticals Corp. (PHIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
A potential skin cancer treatment completed a clinical study. Phio will discuss next steps Sept. 30. - Stock Titan
Live Phio Pharmaceuticals Corp. (PHIO) Technical Analysis - Traders Union
Phio Pharmaceuticals Corp. Stock Price Prediction: Today, Tomorrow, Next Week (PHIO) - Traders Union
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - kalkine.com.au
Phio Pharmaceuticals (NASDAQ: PHIO) Director Patricia A. Bradford Acquires 12,000 Shares at $1.03 Each - Kalkine Media
Phio Pharmaceuticals (PHIO) director buys shares with no 10b5-1 plan reported - Stock Titan
Phio Pharmaceuticals (PHIO) CEO has 68,550 shares withheld for taxes - Stock Titan
Phio Announces Key Development Milestone for PH-762 with FDA - openPR.com
Phio Pharmaceuticals (PHIO) CFO’s 12,888-share tax move involves no market sale - Stock Titan
Phio Announces PH-762 Milestone with FDA Submission Supporting Clinical Development in Cutaneous Squamous Cell Carcinoma - EIN News
Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com Nigeria
King of Prussia's Phio Pharmaceuticals Submits FDA Briefing Package to Advance Its Skin Cancer Gene-Silencing Therapy - BioBuzz
Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial - TipRanks
Phio Pharmaceuticals submits FDA briefing for PH-762 study By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals submits FDA briefing for PH-762 study - Investing.com
Plans for a skin-cancer study reach the FDA after Phio completes an early trial - Stock Titan
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Phio Pharmaceuticals to present clinical updates on cancer treatment PH-762 at H.C. Wainwright conference - Pluang
A potential nonsurgical treatment for skin cancers will be discussed at an investor conference - Stock Titan
PHIO Q2 2026 Earnings: EPS of -$0.36 Slightly Beats Consensus as Company Remains Pre-RevenueCEO Earnings Statement - dars.gov.et
Phio Pharmaceuticals Corp (PHIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
PHIO Should I Buy - Intellectia AI
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada
Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - stocktitan.net
Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus
Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan
Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894 - Bitget
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 - TMX Newsfile
Phio Pharmaceuticals Receives U.S. Notice of Allowance for PH-894 Patent Targeting BRD4 Protein via INTASYL® Platform - kalkine.ca
Enterprise value to revenue forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp. Q2 2026: Net income $(4.14)M, EPS $(0.36) — 10-Q Summary - TradingView
Phio Pharmaceuticals posts $4.1M Q2 net loss, cash $13.0M; advances PH-762 program - TradingView
PHIO: PH-762 clinical progress accelerates as cash runway extends into 2027 amid rising R&D costs - TradingView
PHIO: Q2 2026 net loss widened to $4.1M as PH-762 advanced, with $13M in cash and ongoing funding needs - TradingView
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update - TMX Newsfile
PHIO Q2'26 Earnings: EPS estimate is (0.36) USD - TradingView
Phio Pharmaceuticals (PHIO) Rises 2.91% as Shares Hold Above Key $1.01 SupportExhaustion Gap - dars.gov.et
Phio Pharmaceuticals (NASDAQ:PHIO) secures patent milestone as PH-762 skin cancer program nears FDA meeting - kalkine.com.au
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):